Steve Turley joins UCB as Managing Director for UK and Ireland

He will also become a member of UCB's European Leadership Team

UCB has announced that Steve Turley has joined the firm as Managing Director for the UK and Ireland. Turley will also be an integral member of UCB’s European Leadership Team and will report to Khoso Baluch, Head of EMEA Operations.

Turley brings more than 20-years of commercial experience in the biopharmaceutical industry to the firm, gained at MSD, Roche, Actelion and most recently at Lundbeck. He has worked across a range of primary and speciality therapy areas at both local and international levels.

Turley's career began as a sales representative with MSD before moving to Roche where he held senior roles in Marketing as Business Unit Director, as well as gaining international experience. He went on to become General Manager at Actelion and in the past five years was Managing Director at Lundbeck UK and Ireland.

You may also like

Ingredients

Therapeutic: rozanolixizumab for generalised myasthenia gravis

Generalised myasthenia gravis (gMG) is a rare disease with symptoms that include severe muscular weakness and which is characterised by dysfunction and damage at the neuromuscular junction
Ingredients

Therapeutic: zilucoplan for myasthenia gravis

The rare disease myasthenia gravis (MG) is an autoimmune condition that causes muscle weakness, particularly of those in the face, eyes and that control swallowing
Ingredients

Therapeutics: rozanolixizumab for primary immune thrombocytopenia

Primary immune thrombocytopenia (ITP) is a rare acquired autoimmune disorder. Most patients have pathogenic IgG autoantibodies that target platelets and their precursor megakaryocytes
Ingredients

Therapeutics: dapirolizumab for systemic lupus erythematosus

Although there have been some advances in recent years, systemic lupus erythematosus (SLE) remains a significant unmet medical need
Manufacturing

UCB Pharma chooses South Korean CDMO for the third time

Samsung Biologics will now produce UCB’s anti-tau candidate for Belgian pharma company to treat progressive supranuclear palsy
Packaging

Pharmapack Europe 2019 reveals winners

Award winners have been selected for innovation in delivery, dosage and packaging of pharmaceutical products
Pharmaceutical

Increasing competition in the psoriasis market

UCB, a global biopharmaceutical company, has potential to compete in the psoriasis market with Cimzia FDA approval, says GlobalData
Subscribe now